Multicellular living organisms and unmodified parts thereof and – Method of introducing a polynucleotide molecule into or... – Nonplant protein is expressed from the polynucleotide
Reexamination Certificate
2004-03-05
2009-12-15
Worley, Cathy Kingdon (Department: 1638)
Multicellular living organisms and unmodified parts thereof and
Method of introducing a polynucleotide molecule into or...
Nonplant protein is expressed from the polynucleotide
C435S468000
Reexamination Certificate
active
07632983
ABSTRACT:
Methods, nucleic acid sequences, and transformed duckweed plant or duckweed nodule cultures for the expression and the secretion of biologically active polypeptides from genetically engineered duckweed are provided. Expression of recombinant polypeptides in duckweed is improved by modifying the nucleotide sequence of the expression cassette encoding the polypeptide for improved expression in duckweed. Recovery of biologically active polypeptides from duckweed is improved by linking the biologically active polypeptide to a signal peptide that directs the secretion of the polypeptide into the culture medium. Methods of producing recombinant monoclonal antibodies having effector function, and antibodies produced by these methods are provided.
REFERENCES:
patent: 4956282 (1990-09-01), Goodman et al.
patent: 5202422 (1993-04-01), Hiatt et al.
patent: 5460952 (1995-10-01), Yu et al.
patent: 5629175 (1997-05-01), Goodman et al.
patent: 5850032 (1998-12-01), Wann
patent: 5959177 (1999-09-01), Hein et al.
patent: 5994628 (1999-11-01), Rodriguez
patent: 6020169 (2000-02-01), Lee et al.
patent: 6040498 (2000-03-01), Stomp et al.
patent: 6066781 (2000-05-01), Sutliff et al.
patent: 6096546 (2000-08-01), Raskin
patent: 6096547 (2000-08-01), Goodman et al.
patent: 2003/0115640 (2003-06-01), Stomp et al.
patent: 2003/0175711 (2003-09-01), Renner et al.
patent: 0 141 484 (1985-05-01), None
patent: WO 94/21796 (1994-09-01), None
patent: WO 98/21348 (1998-05-01), None
patent: WO 98/36085 (1998-08-01), None
patent: WO 99/07210 (1999-02-01), None
patent: WO 99/07210 (1999-02-01), None
patent: WO 99/19497 (1999-04-01), None
patent: WO 99/47678 (1999-09-01), None
patent: WO 00/34490 (2000-06-01), None
patent: WO 01/31045 (2001-03-01), None
patent: WO 01/29242 (2001-04-01), None
patent: WO/02/10414 (2002-02-01), None
patent: WO 02/070672 (2002-09-01), None
patent: WO 03/060071 (2003-07-01), None
Michaelsen et al. One disulfide bond in front of the second heavy chain constant region is necessary and sufficient for effector functions of human IgG3 without a genetic hinge. (1994) PNAS, vol. 91, pp. 9243-9247.
Joshi et al. Context sequences of translational initiation codon in plants. (1997) PMB vol. 35, pp. 993-1001.
Callis et al. Introns increase gene expression in cultured maize cells. (1987) Genes and Development, vol. 1, pp. 1183-1200.
Greenwood et al. Structural motifs invovled in human IgG antibody effector functions. (1993) Eur. J. Immunol. vol. 23, pp. 1098-1104.
Buzby et al. A light-regulated DNA-binding activity interacts with a conserved region of aLemna gibbarbcS promoter. (1990) The Plant Cell, vol. 2, pp. 805-814.
Buzby et al. SSU5B=ribulose-1,5-bisphosphate carboxylase small subunit. (1993) GenBank Accession S45167 pp. 1-2.
Fischer, R., & Emans, N., “Molecular Farming of Pharmaceutical Proteins,”Transgenic Research, 2000, pp. 279-299, vol. 9, No. 4-5.
Schillberg, S., et al., “Molecular Farming of Recombinant Antibodies in Plants,”CMLS, Cell. Mol. Life Sci., Mar. 2003, pp. 433-445, vol. 60, No. 3.
Stiekema, W. J., et al., “Nucleotide Sequence Encoding the Precursor of the Small Subunit of Ribulose 1,5-Bisphosphate Carboxylase fromLemna gibbaL.G-3,”Nucleic Acids Research, Nov. 25, 1983, pp. 8051-8061, vol. 11, No. 22.
Conrad, U., et al., “Single-Chain Fv Antibodies Expressed in Plants,”Methods in Biotechnology, 1988, pp. 103-127, vol. 3.
Yamamoto, Y.T., “Genetic Transformation of Duckweed Lemma Gibba and Lemna Minor,” In VitroCell. Dev. Biol.—Plant, May-Jun. 2001, pp. 349-353, vol. 37, No. 3.
Buzby, J. S. et al., “A Light-Regulated DNA-Binding Activity Interacts with a Conserved Region of aLemna gibba rbcSPromoter,”The Plant Cell, Aug. 1990, pp. 805-814, vol. 2.
Bakker, H., et al., “Galactose-extended Glycans of Antibodies Produced by Transgenic Plants,”PNAS, Feb. 27, 2001, pp. 2899-2904, vol. 98, No. 5.
Brekke, O.H. and Inger, S., “Therapeutic Antibodies for Human Diseases at the Dawn of the Twenty-First Century,”Nature Reviews, Jan. 2003, pp. 52-62, vol. 2.
Chadd, H.E., and Chamow, S.M., “Therapeutic Antibody Expression Technology,”Current Opinion in Biotechnology, 2001, pp. 188-194, vol. 12.
Chargelegue, D., et al., “A Murine Monoclonal Antibody Produced in Transgenic Plants with Plant-specific Glycans is Not Immunogenic in Mice,” Transgenic Research, 2000, pp. 187-194, vol. 9.
Fischer, R., et al., “Affinity-purification of a TMV-specific Recombinant Full-size Antibody from a Transgenic Tobacco Suspension Culture,”Journal of Immunological Methods, 1999, pp. 1-10, vol. 226.
Gasdaska, J.R., et al., “Advantages of Therapeutic Protein Production in the Aquatic PlantLemna,” BioProcessing Journal, Mar./Apr. 2003, vol. 2, No. 2.
Humphreys, D.P., and Glover, D.J., “Therapeutic Antibody Production Technologies: Molecules, Applications, Expression and Purification,”Current Opinion in Drug Discovery&Development, 2001, pp. 172-185, vol. 4, No. 2.
Ko, K., et al., “Function and Glycosylation of Plant-derived Antiviral Monoclonal Antibody,”PNAS, Jun. 24, 2003, pp. 8013-8018, vol. 100, No. 13.
Lerouge, P. et al., “N-Glycoprotein Biosynthesis in Plants: Recent Developments and Future Trends,”Plant Molecular Biology, 1998, pp. 31-48, No. 38.
Lerouge, P., et al., “N-Glycosylation of Recombinant Pharmaceutical Glycoproteins Produced in Transgenic Plants: Towards an Humanisation of Plant N-Glycans,”Current Pharmaceutical Biotechnology, 2000, pp. 347-354, vol. 1, No. 4.
Murray, E. E. et al., “Codon Usage in Plant Genes,”Nucleic Acids Research, Jan. 25, 1989, pp. 477-498, vol. 17, No. 2.
Palacpac, N.Q., et al., “Stable Expression of Human β1, 4-galactosyltransferase in Plant Cells Modifies N-linked Glycosylation Patterns,”Proc. Natl. Acad. Sci., Apr. 1999, pp. 4692-4697, vol. 96.
Raju, T.S., “Glycosylation Variations with Expression Systems and Their Impact on Biological Activity of Therapeutic Immunoglobulins,”Bioprocess International, Apr. 2003, pp. 44-53.
Ramirez, N., et al., “Expression and Characterization of an Anti-(hepatitis B surface antigen) Glycosylated Mouse Antibody in Transgenic Tobacco (Nicotiana tabacum) Plants and Its Use in the Immunopurification of Its Target Antigen,”Biotechnol. Appl. Biochem., 2003, pp. 223-230, vol. 38.
Stoger, E., et al., “Plantibodies: Applications, Advantages and Bottlenecks,”Current Opinion in Biotechnology, 2002, pp. 161-166, vol. 13.
Cox Kevin M.
Dickey Lynn F.
Gasdaska John R.
Peele Charles G.
Spencer David
Alston & Bird LLP
Biolex Therapeutics, Inc.
Kingdon Worley Cathy
LandOfFree
Expression of monoclonal antibodies in duckweed does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Expression of monoclonal antibodies in duckweed, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Expression of monoclonal antibodies in duckweed will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4053180